Pitch & Partner 2018

The orphan drug industry has matured considerably in the past decade. With that, more orphan drugs get approved, while pharma and biotechs get closer to launch new and innovative therapies for rare disease patients. Their focus has shifted from early stage challenges to strategies on commercialization, marketing, pricing and reimbursement.
As these companies move from pre-revenue to commercial and start recouping the investments from years of R&D, more capital starts to flood into promising new biotechs, and consolidation starts to rise. VCs investment in orphan drugs biotechs has grown from $101 million in 2005 to over $346 million in 2014, according to Pitch Book.
From VCs to pharma investors, funding is a much more optimistic reality for orphan drug biotechs. However there are still major challenges and uncertainties in terms of how investors assess these investment opportunities. Evolving regulatory guidelines, increased scrutiny over orphan drugs high price, policies risk, and the common R&D failures, are some of the key areas impacting investment decisions in this market. 
The lack of a platform for orphan drug biotechs to meet and present their development programs to investors contributed to the launch of Pitch & Partner at the World Orphan Drug Congress USA.

Pitch & Partner 2017 featured:  

VC Panel: Investing in the orphan drug space – targeting big business by treating a small number of patients

World Orphan Drug Congress USA 2018

Jeremy Springhorn
Flagship Ventures

World Orphan Drug Congress USA 2018

Ari Brettman
Clarus Ventures

World Orphan Drug Congress USA 2018

Chen Yu
Managing Partner
Vivo Capital

World Orphan Drug Congress USA 2018

Stephen Squinto
Venture Partner

World Orphan Drug Congress USA 2018

Philip Ross
Managing Director
J.P. Morgan Healthcare Investment Banking

From venture capital to the launch of a rare disease biotech – unlocking the druggable mechanisms that regulate disease genes

Walter Kowtoniuk
Director, Strategy and Operations
Fulcrum Therapeutics

Applying the virtual startup model to orphan drug development – Lumos Pharma case study

John McKew
Chief Scientific Officer 
Lumos Pharma

2017 Presenting Companies Included: 

  • Acer Therapeutic Inc.

  • Adverum Biotechnologies, Inc. 

  • Agilis Biotherapeutics 

  • Alkeus Pharmaceuticals, Inc. 

  • Andarix Pharmaceuticals 

  • ArmaGen Inc. 

  • Cantex Pharmaceuticals 

  • DNX Biopharmaceuticals, Inc. 

  • Eiger BioPharmaceuticals, Inc. 

  • EmeraMed Ltd 

  • Fibrocell Science 

  • Minoryx 

  • NeuroHealing Pharmaceuticals, Inc.

  • Soligenix, Inc. (Nasdaq: SNGX) 

  • SOM Biotech 

  • Thetis Pharmaceuticals LLC 

  • Valley Fever Solutions 

If your organization provides contract research services, funding, financial support, and other solutions for small and mid-size orphan drug biotechs you can sponsor Pitch & Partner to stay front of mind of your prospects!



Contact Andre Singer at andre.singer@terrapinn.com
or  +1 646 619 1797

Stay connected

Sign up for event updates